tbuckley/cabot-search huggingface dataset:
Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis
Authors: Rui Li, Xuefei Liu, Xudong Huang, Di Zhang, Ziming Chen, Jialiang Zhang, Ruihong Bai, Shaoping Zhang, Hongzhe Zhao, Zilan Xu, Lingxing Zeng, Lisha Zhuang, Shujuan Wen, Shaojia Wu, Mei Li, Zhixiang Zuo, Junzhong Lin, Dongxin Lin, Jian Zheng
Journal: Gut (2023)

Objective Metastasis is the major cause of cancer death. However, what types of heterogenous cancer cells in primary tumour and how they metastasise to the target organs remain largely undiscovered. Design We performed single-cell RNA sequencing and spatial transcriptomic analysis in primary colorectal cancer (CRC) and metastases in the liver (lCRC) or ovary (oCRC). We also conducted immunofluorescence staining and functional experiments to examine the mechanism. Results Integrative analyses of epithelial cells reveal a stem-like cell cluster with high protein tyrosine phosphatase receptor type O ( PTPRO ) and achaete scute-like 2 ( ASCL2 ) expression as the metastatic culprit. This cell cluster comprising distinct subpopulations shows distinct liver or ovary metastatic preference. Population 1 (P1) cells with high delta-like ligand 4 (DLL4) and MAF bZIP transcription factor A (MAFA) expression are enriched in primary CRC and oCRC, thus may be associated with ovarian metastasis. P3 cells having a similar expression pattern as cholangiocytes are found mainly in primary CRC and lCRC, presuming to be likely the culprits that specifically metastasise to the liver. Stem-like cells interacted with cancer-associated fibroblasts and endothelial cells via the DLL4-NOTCH signalling pathway to metastasise from primary CRC to the ovary. In the oCRC microenvironment, myofibroblasts provide cancer cells with glutamine and perform a metabolic reprogramming, which may be essential for cancer cells to localise and develop in the ovary. Conclusion We uncover a mechanism for organ-specific CRC metastasis.
Symptom-related screening programme for early detection of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the SYSPPE study
Authors: Samira Marin-Romero, Aitor Ballaz-Quincoces, Covadonga Gómez-Cuervo, Pablo Javier Marchena-Yglesias, Patricia Lopez-Miguel, Iria Francisco-Albesa, Jose Maria Pedrajas-Navas, Marina Lumbierres, Miguel Angel Aibar-Arregui, Juan Bosco Lopez-Saez, Montserrat Perez-Pinar, Carlos Baeza-Martinez, Antoni Riera-Mestre, Marisa Peris-Sifre, Jose Antonio Porras-Ledantes, Juan Criado-Garcia, Teresa Elias-Hernandez, Remedios Otero, Maria Barca-Hernando, Alfonso Muriel, Frederikus A Klok, Luis Jara-Palomares
Journal: Thorax (2023)

Background Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe long-term complication of acute pulmonary embolism (PE). We aimed to evaluate the impact of a symptom screening programme to detect CTEPH in PE survivors. Methods This was a multicentre cohort study of patients diagnosed with acute symptomatic PE between January 2017 and December 2018 in 16 centres in Spain. Patients were contacted by phone 2 years after the index PE diagnosis. Those with dyspnoea corresponding to a New York Heart Association (NYHA)/WHO scale≥II, visited the outpatient clinic for echocardiography and further diagnostic tests including right heart catheterisation (RHC). The primary outcome was the new diagnosis of CTEPH confirmed by RHC. Results Out of 1077 patients with acute PE, 646 were included in the symptom screening. At 2 years, 21.8% (n=141) reported dyspnoea NYHA/WHO scale≥II. Before symptom screening protocol, five patients were diagnosed with CTEPH following routine care. In patients with NYHA/WHO scale≥II, after symptom screening protocol, the echocardiographic probability of pulmonary hypertension (PH) was low, intermediate and high in 76.6% (n=95), 21.8% (n=27) and 1.6% (n=2), respectively. After performing additional diagnostic test in the latter 2 groups, 12 additional CTEPH cases were confirmed. Conclusions The implementation of this simple strategy based on symptom evaluation by phone diagnosed more than doubled the number of CTEPH cases. Dedicated follow-up algorithms for PE survivors help diagnosing CTEPH earlier. Trial registration number NCT03953560 .
Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment
Authors: Shilpa Gupta, Alexander Andreev-Drakhlin, Otto Fajardo, Marcella Fassò, Jorge A Garcia, Christopher Wee, Carsten Schröder
Journal: JNCI Journal of the National Cancer Institute (2023)

This study examined real-world patients with locally advanced or metastatic urothelial carcinoma considered ineligible for platinum-containing chemotherapy in the first-line setting.
Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies
Authors: Hilde Julie T Lien, Tina T Pedersen, Bente Jakobsen, Arnar Flatberg, Konika Chawla, Pål Sætrom, Mona H Fenstad
Journal: Annals of the Rheumatic Diseases (2023)

Objectives Comparative longitudinal analyses of cellular composition and peripheral blood gene expression in Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and healthy pregnancies. Methods In total, 335 whole blood samples from 84 RA, SLE and healthy controls before pregnancy, at each trimester, 6 weeks, 6 months and 12 months post partum were analysed. We combined bulk and single cell RNA analyses for cell-type estimation, validated by flow cytometry, before combining this in a cell-type adjusted analysis for an improved resolution of unrecognised gene expression changes associated with RA and SLE pregnancies. Results Patients were well regulated throughout pregnancy, and few had pregnancy complications. In SLE, the interferon signature was augmented during pregnancy, and the pregnancy signature was continued post partum. An altered cell type composition strongly influences the profile. In the pregnancy signature, transcripts involved in galactosylation potentially altering the effector functions of autoantibodies became more evident. Several genes in the adjusted RA signature are expressed in mucosal associated invariant T cells. Conclusion We found distinct RA, SLE and pregnancy signatures, and no expression patterns could be attributed to medication or disease activity. Our results support the need for close postpartum follow-up of patients with SLE. Gene expression patterns in RA were closer to healthy controls than to SLE, and primarily became evident after cell-type adjustment. Adjusting for cell abundance unravelled gene expression signatures less associated with variation in cell-composition and highlighted genes with expression profiles associated with changes in specialised cell populations.
Maternal SARS-CoV-2 infection during pregnancy and subsequent risk of atopic dermatitis in offspring: a nationwide birth cohort study in South Korea
Authors: Minji Kim, Yujin Choi, Myeongcheol Lee, Jiseung Kang, So Min Kang, Dong-Geol Lee, Dong Keon Yon
Journal: British Journal of Dermatology (2023)

Although previous studies suggest an association between SARS-CoV-2 infection and atopic dermatitis (AD) in adults, insufficient attention has been given to the impact of SARS-CoV-2 infection on pregnant woman and their offspring. Evidence on prenatal SARS-CoV-2 infection and subsequent risk of AD is lacking; therefore, we aimed to investigate the risk of AD in infants born to women who were infected with SARS-CoV-2 during pregnancy.
Smart stimuli-responsive drug delivery systems in spotlight of COVID-19
Authors: Zeinab Najjari, Farzaneh Sadri, Jaleh Varshosaz
Journal: Asian Journal of Pharmaceutical Sciences (2023)

The world has been dealing with a novel severe acute respiratory syndrome (SARS-CoV-2) since the end of 2019, which threatens the lives of many people worldwide. COVID-19 causes respiratory infection with different symptoms, from sneezing and coughing to pneumonia and sometimes gastric symptoms. Researchers worldwide are actively developing novel drug delivery systems (DDSs), such as stimuli-responsive DDSs. The ability of these carriers to respond to external/internal and even multiple stimuli is essential in creating "smart" DDS that can effectively control dosage, sustained release, individual variations, and targeted delivery. To conduct a comprehensive literature survey for this article, the terms "Stimuli-responsive", "COVID-19" and "Drug delivery" were searched on databases/search engines like "Google Scholar", "NCBI", "PubMed", and "Science Direct". Many different types of DDSs have been proposed, including those responsive to various exogenous (light, heat, ultrasound and magnetic field) or endogenous (microenvironmental changes in pH, ROS and enzymes) stimuli. Despite significant progress in DDS research, several challenging issues must be addressed to fill the gaps in the literature. Therefore, this study reviews the drug release mechanisms and applications of endogenous/exogenous stimuli-responsive DDSs while also exploring their potential with respect to COVID-19.
Carcinogenicity of perfluorooctanoic acid and perfluorooctanesulfonic acid
Authors: Shelia Zahm, Jens Peter Bonde, Weihsueh A Chiu, Jane Hoppin, Jun Kanno, Mohamed Abdallah, Chad R Blystone, Miriam M Calkins, Guang-Hui Dong, David C Dorman, Rebecca Fry, Huan Guo, Line S Haug, Jonathan N Hofmann, Motoki Iwasaki, Miroslav Machala, Francesca R Mancini, Silvya S Maria-Engler, Peter Møller, Jack C Ng, Marc Pallardy, Gloria B Post, Samira Salihovic, Jennifer Schlezinger, Anatoly Soshilov, Kyle Steenland, Inger-Lise Steffensen, Volodymyr Tryndyak, Alexandra White, Susan Woskie, Tony Fletcher, Ayat Ahmadi, Nahid Ahmadi, Lamia Benbrahim-Tallaa, Wendy Bijoux, Shirisha Chittiboyina, Aline de Conti, Caterina Facchin, Federica Madia, Heidi Mattock, Mira Merdas, Elisa Pasqual, Eero Suonio, Susana Viegas, Ljubica Zupunski, Roland Wedekind, Mary K Schubauer-Berigan
Journal: The Lancet Oncology (2023)
Prevalence of headaches and their relationship with obstructive sleep apnea (OSA) - Systematic review and meta-analysis
Authors: Bartłomiej Błaszczyk, Helena Martynowicz, Mieszko Więckiewicz, Marcin Straburzyński, Mariola Antolak, Sławomir Budrewicz, Martyna Staszkiewicz, Anna Kopszak, Marta Waliszewska-Prosół
Journal: Sleep Medicine Reviews (2023)
Miniaturized Capsule System Toward Real‐Time Electrochemical Detection of H<sub>2</sub>S in the Gastrointestinal Tract
Authors: Justin M. Stine, Katie L. Ruland, Luke A. Beardslee, Joshua A. Levy, Hossein Abianeh, Santiago Botasini, Pankaj J. Pasricha, Reza Ghodssi
Journal: Advanced Healthcare Materials (2023)

Hydrogen sulfide (H
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Authors: Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James P Buteau, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie K Rutherford, Andrew Weickhardt, Andrew M Scott, Sze-Ting Lee, Edmond M Kwan, Arun A Azad, Shakher Ramdave, Andrew D Redfern, William Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Yan Zhang, Martin R Stockler, Scott G Williams, Andrew J Martin, Ian D Davis, Tim Akhurst, Ramin Alipour, Dale Bailey, Patricia Banks, Alexis Beaulieu, Louise Campbell, Megan Crumbaker, Nattakorn Dhiantravan, Anis Hamid, Mohammad Haskali, Terry Hung, Grace Kong, Nick Lawrence, Jeremy Lewin, Michael McCarthy, Kate Moodie, Declan Murphy, Andrew Nguyen, David Pook, Aravind Ravi Kumar, Paul Roach, Peter Roselt, Javad Saghebi, Geoff Schembri, Lavinia Spain, Shalini Subramaniam, Sue Ping Thang, Paul Thomas, Ben Tran, Roslyn Wallace, Sonia Yip
Journal: The Lancet Oncology (2023)
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis
Authors: Spyridon Siafis, Lasse Brandt, Robert A McCutcheon, Stefan Gutwinski, Johannes Schneider-Thoma, Irene Bighelli, John M Kane, Celso Arango, René S Kahn, W Wolfgang Fleischhacker, Patrick McGorry, William T Carpenter, Peter Falkai, Alkomiet Hasan, Stephen R Marder, Nina Schooler, Rolf R Engel, William G Honer, Robert W Buchanan, Michael Davidson, Mark Weiser, Josef Priller, John M Davis, Oliver D Howes, Christoph U Correll, Stefan Leucht
Journal: The Lancet Psychiatry (2023)
Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study
Authors: Antoine Nkuba-Ndaye, Angele Dilu-Keti, Tamara Tovar-Sanchez, Mamadou Saliou Kalifa Diallo, Daniel Mukadi-Bamuleka, Richard Kitenge, Pierre Formenty, Anaïs Legand, François Edidi-Atani, Guillaume Thaurignac, Raphael Pelloquin, Placide Mbala-Kingebeni, Abdoulaye Toure, Ahidjo Ayouba, Jean-Jacques Muyembe-Tamfum, Eric Delaporte, Martine Peeters, Steve Ahuka-Mundeke, Steve Ahuka-Mundeke, Nella Bisento-Ngafa, Junior Bulabula-Penge, Bernice Danga-Yema, François Eddi-Atani, Eddy Kinganda-Lusamaki, Antoine Nkuba-Ndaye, Fabrice Mambu Mbika, Gabriel Kabamba Lungenyi, Meris Matondo Kiamfumu, Placide Mbala-Kingebeni, Daniel Mukadi-Bamuleka, Jean-Jacques Muyembe-Tamfum, Eric Delaporte, Ahidjo Ayouba, Julie Boullin, Angèle Dilu-Keti, Audrey Lacroix, Martine Peeters, Raphael Pelloquin, Guillaume Thaurignac, Tamara Tovar Sanchez, Richard Kitenge, Pierre Formenty, Anaïs Legand, Eric Panzi-Kalunda, Callixte Kakule-Sadiki, Guillaume Kambale-Kasyamboko, Nelson Kambale-Sivihwa, Sheila Kavira-Muhesi, Eli Kavoyo-Mbayayi, Divine Kitsa-Mutsumbirwa, Fyfy Mbelu-Matulu, Noella Mulopo-Mukanya, Elias Mumbere-Kalemekwa, None Defao, Grace Paluku-Salambongo, None Ekoko, Abdoulaye Touré, Mamadou Saliou Kalifa Diallo
Journal: The Lancet Infectious Diseases (2023)
Design consideration of phthalocyanines as sensitizers for enhanced sono-photodynamic combinatorial therapy of cancer
Authors: Lindokuhle Cindy Nene, Heidi Abrahamse
Journal: Acta Pharmaceutica Sinica B (2023)

Cancer remains one of the diseases with the highest incidence and mortality globally. Conventional treatment modalities have demonstrated threatening drawbacks including invasiveness, non-controllability, and development of resistance for some, including chemotherapy, radiation, and surgery. Sono-photodynamic combinatorial (SPDT) therapy has been developed as an alternative treatment modality which offers a non-invasive and controllable therapeutic approach. SPDT combines the mechanism of action of sonodynamic therapy (SDT), which uses ultrasound, and photodynamic therapy (PDT), which uses light, to activate a sensitizer and initiate cancer eradication. The use of phthalocyanines (Pcs) as sensitizers for SPDT is gaining interest owing to their ability to induce intracellular oxidative stress and initiate toxicity under SDT and PDT. This review discusses some of the structural prerequisites of Pcs which may influence their overall SPDT activities in cancer therapy.
Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors
Authors: Catherina X. Pan, Mofei Liu, Charles B. Lau, William C. Lau, Daniel Y. Kim, Shahin A. Saberi, Rachael Rowley, Ruhi Kanwar, Anita Giobbie-Hurder, Nicole R. LeBoeuf, Vinod E. Nambudiri
Journal: Journal of the American Academy of Dermatology (2023)
Balanced crystalloids versus saline for critically ill patients (BEST-Living): a systematic review and individual patient data meta-analysis
Authors: Fernando G Zampieri, Alexandre B Cavalcanti, Gian Luca Di Tanna, Lucas P Damiani, Naomi E Hammond, Flavia R Machado, Sharon Micallef, John Myburgh, Mahesh Ramanan, Balasubramanian Venkatesh, Todd W Rice, Matthew W Semler, Paul J Young, Simon Finfer
Journal: The Lancet Respiratory Medicine (2023)
The evolutionary tug-of-war of macrophage metabolism during bacterial infection
Authors: Luís Almeida, Ayesha Dhillon-LaBrooy, Tim Sparwasser
Journal: Trends in Endocrinology and Metabolism (2023)

The function and phenotype of macrophages are intimately linked with pathogen detection. On sensing pathogen-derived signals and molecules, macrophages undergo a carefully orchestrated process of polarization to acquire pathogen-clearing properties. This phenotypic change must be adequately supported by metabolic reprogramming that is now known to support the acquisition of effector function, but also generates secondary metabolites with direct microbicidal activity. At the same time, bacteria themselves have adapted to both manipulate and take advantage of macrophage-specific metabolic adaptations. Here, we summarize the current knowledge on macrophage metabolism during infection, with a particular focus on understanding the ‘arms race’ between host immune cells and bacteria during immune responses.
Eating disorders: are gut microbiota to blame?
Authors: Jiayi Xu, Ian M. Carroll, Laura M. Huckins
Journal: Trends in Molecular Medicine (2023)

Gut microbiota could be involved in weight regulation and impact brain function via the gut–brain axis. Moreover, gut microbiota may impact the development of eating disorders (EDs) since they are characterized by weight-related concerns and symptoms and may represent a therapeutic target if future research can establish a causal link.
Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment
Authors: Xiaolan Xu, Jiaming Zhang, Tao Wang, Jing Li, Yukang Rong, Yanfang Wang, Chenxia Bai, Qing Yan, Xiaohua Ran, Yingli Wang, Tianhong Zhang, Jin Sun, Qikun Jiang
Journal: Acta Pharmaceutica Sinica B (2023)

The non-selective cytotoxicity of toxins limits the clinical relevance of the toxins. In recent years, toxins have been widely used as warheads for antibody‒drug conjugates (ADCs) due to their efficient killing activity against various cancer cells. Although ADCs confer certain targeting properties to the toxins, low drug loading capacity, possible immunogenicity, and other drawbacks also limit the potential application of ADCs. Recently, non-ADC delivery strategies for toxins have been extensively investigated. To further understand the application of toxins in anti-tumor, this paper provided an overview of prodrugs, nanodrug delivery systems, and biomimetic drug delivery systems. In addition, toxins and their combination strategies with other therapies were discussed. Finally, the prospect and challenge of toxins in cancer treatment were also summarized.
Lipid Nanoparticle Library Towards Development of Next Generation Genomic Medicines
Authors: Nikita Jain, Sedigheh Nazaripour, Zhengyu Chen, Suraj Abraham, Leanna Yee, Sams Sadat, Gayatri Mehar Namala, Helena “” Son, Sijo Chemmannur, Kobe Tickner, Malathi Anantha, Ruchi Sharma, Sri Abbina, Seetalakshmi Thambatti, Vinay Mayya, Emily Soon, Jay Paquette, Anitha Thomas, Viet Nguyen
Journal: Blood (2023)
Correlation of Flow Cytometric BCL2 and MCL1 Expression with Cytogenetic Characteristics and Outcome in Multiple Myeloma
Authors: Shelly Singla, Sreejesh Sreedharanunni, Archana Singh, Anand Balakrishnan, Anshu Anshu, Shailja Rathore, Parveen Bose, Man Updesh Singh Sachdeva, Praveen Sharma, Nabhajit Mallik, Reena Das, Deepesh Pravinkumar Lad, Pankaj Malhotra
Journal: Blood (2023)
The Comparison of Platelet-Derived Microparticles between Ambulatory Cancer Patients and Controls
Authors: Sirichai Srichairatanakool, Narisara Paradee, Piangrawee Niprapan, Somdet Srichairatanakool, Nonthakorn Hantrakun, Teerachat Punnachet, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Ekarat Rattarittamrong, Adisak Tantiworawit, Lalita Norasetthada, Chatree Chaiadisaksopha
Journal: Blood (2023)
Real-World Outcomes of Zanubrutinib Monotherapy in Chronic Lymphocytic Leukemia: A Multicenter Retrospective Study
Authors: Jing Luo, Jiaojiao Zhang, Ligen Liu, Rong Wei, Yonghua Yao, Min Xu, Jie Xu, Jumei Shi, Jianmin Yang, Jian Hou, Jin Wang, Jian-Qing Mi
Journal: Blood (2023)
Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy
Authors: David Sibon, Jean Marc Schiano De Colella, Emmanuel Itti, Thu-Ha Dao, Lucie Oberic, Romain Ricci, Camille Laurent, Luc Xerri, Marc André, Emmanuelle Nicolas Virelizier, Christophe Bonnet, Alexandre Karangwa, Luc-Matthieu Fornecker, Emmanuel Bachy, Marie Bannier, Alexandra Traverse-Glehen, Youlia Kirova, Cyrielle de Lacheisserie, Romain Ould-Ammar, Patrick Fogarty, Nadia Amara, Virginie Fataccioli, Hervé Tilly, Lionel Tortolano, Romain Bosc, Fabien Le Bras, Philippe Gaulard, Corinne Haioun
Journal: Blood (2023)
Phase I/II Study of Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone (BelCyd) in Relapsed/Refractory Multiple Myeloma
Authors: Ashraf Z. Badros, Thea Nash, Christopher Lawrance, Brandon Tittle, Sunita Philip, Sarah Sunshine, Wuqaas Munir, Xiaoxuan Fan, Christina Ide, Djordje Atanackovic
Journal: Blood (2023)
Lenalidomide Maintenance in Multiple Myeloma: A Retrospective, Nationwide, Real-World Study
Authors: Mads Harsløf, Iman Chanchiri, Trine Silkjær, Ulf Christian Frølund, Elena Manuela Teodorescu, Kristina Buchardi Nielsen, Per Ishøy Nielsen, Per Trøllund Pedersen, Katrine Fladeland Iversen, Kirsten Grønbæk, Annette J. Vangsted, Sigrun Thorsteinsdottir, Agoston Gyula Szabo
Journal: Blood (2023)
ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with Ruxolitinib
Authors: Matthew C. Stubbs, Michelle Pusey, Xiaoming Wen, Katherine Drake, Nina Zolotarjova, Amanda Smith, Maryanne Covington, Guofeng Zhang, Ricardo Macarrón, Sunkyu Kim
Journal: Blood (2023)
A Prognostic Model Integrating Circulating Clonal Plasma Cells into R-ISS and PET-CT Based Tumor Burden in Transplant-Ineligible Multiple Myeloma
Authors: Daisuke Ikeda, Toshiki Terao, Mitsuaki Oura, Atsushi Uehara, Rikako Tabata, Kentaro Narita, Masami Takeuchi, Youichi Machida, Kosei Matsue
Journal: Blood (2023)
Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data
Authors: Matthias Stelljes, Katja Sockel, Matthias Floeth, Johannes Schetelig, Martin Bornhäuser, Christian Reicherts, Georg Lenz, Thomas Schröder, Rudolf Trenschel, Miroslaw Markiewicz, Hélène Labussière-Wallet, Péter Reményi, Fabio Ciceri, Friedrich Stölzel
Journal: Blood (2023)
Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial
Authors: Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Jacqueline S. Garcia, Eric S. Winer, Ilene Galinsky, Julie Bergeron, Julie Asch, Matthew D. Seftel, Richard M Stone, Marlise R. Luskin, Daniel J. DeAngelo
Journal: Blood (2023)
Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)
Authors: Hongyan Tong, Sujun Gao, Wei Yang, Junmin Li, Qingsong Yin, Xingli Zhao, Xiaojing Yan, Sanfang Tu, Fei Li, Haiping Yang, Ronghua Hu, Shaoyuan Wang, Zheng Dong, Yixuan Yang, Zhenjiu Wang, Qiying Lu, Wenzhi Tian, Zhijian Xiao, Jianxiang Wang
Journal: Blood (2023)
Evaluation of the Efficacy and Safety during Treatment with TPO-Ras in 40 SLE-ITP and APS-ITP Patients
Authors: Marques Cindy, Mickael Roussotte, Guillaume Moulis, Bernard Bonnotte, Jean-Francois Viallard, Nathalie Costedoat-Chalumeau, Alban Deroux, Pascal Sève, Bertrand Godeau, Matthieu Mahevas, Marc Michel
Journal: Blood (2023)